Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEOGENOMICS INCNEO · Entity 2096 | President, Clinical Services | May 25, 2021 | May 27, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEOGENOMICS INC
Report date May 25, 2021 · Filed May 27, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 150,101 |
Ending reported balance
After 2021-05-25 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2021-05-25 · Exercise / conversion · Acquired 96,167 · Balance 249,914 Row 2 · 2021-05-25 · Exercise / conversion · Acquired 16,724 · Balance 266,638 Row 3 · 2021-05-25 · Exercise / conversion · Acquired 14,067 · Balance 280,705 Row 4 · 2021-05-25 · Sale · Disposed 130,604 · Balance 150,101 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.03 · Expires 2023-02-26 | Direct | 0 |
Reported balance
After 2021-05-25 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-05-25 · Exercise / conversion · Disposed 96,167 · Balance 0 F2: On February 26, 2018, Mr. Shovlin was granted 288,500 stock options. These options vested ratably over the first three anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.60 · Expires 2024-03-01 | Direct | 33,449 |
Reported balance
After 2021-05-25 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-05-25 · Exercise / conversion · Disposed 16,724 · Balance 33,449 F3: On March 1, 2019, Mr. Shovlin was granted 66,897 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.33 · Expires 2027-03-02 | Direct | 42,204 |
Reported balance
After 2021-05-25 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-05-25 · Exercise / conversion · Disposed 14,067 · Balance 42,204 F4: On March 2, 2020, Mr. Shovlin was granted 56,271 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.17 · Expires 2028-03-02 | Direct | 38,688 |
Reported balance
Holding disclosure · report date 2021-05-25 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 38,688 F1: On March 2, 2021, Mr. Shovlin was granted 38,688 stock options. These options vest ratably over the first four anniversary dates of the grant date |
Filing footnotes · ownership attribution and instrument terms
F1: On March 2, 2021, Mr. Shovlin was granted 38,688 stock options. These options vest ratably over the first four anniversary dates of the grant date
F2: On February 26, 2018, Mr. Shovlin was granted 288,500 stock options. These options vested ratably over the first three anniversary dates of the grant date.
F3: On March 1, 2019, Mr. Shovlin was granted 66,897 stock options. These options vest ratably over the first four anniversary dates of the grant date.
F4: On March 2, 2020, Mr. Shovlin was granted 56,271 stock options. These options vest ratably over the first four anniversary dates of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 25, 2021 Filed May 27, 2021 22:23 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,067 | $0.00 Strike: $28.33 | $0.00 |
DisclosureSEC source: 0001077183-21-000134 · wf-form4_162215415171071.xml · derivative · entry 8 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,204 Underlying: Common Stock · 14,067 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On March 2, 2020, Mr. Shovlin was granted 56,271 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| May 25, 2021 Filed May 27, 2021 22:23 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,724 | $0.00 Strike: $19.60 | $0.00 |
DisclosureSEC source: 0001077183-21-000134 · wf-form4_162215415171071.xml · derivative · entry 7 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,449 Underlying: Common Stock · 16,724 shares Expires 2024-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On March 1, 2019, Mr. Shovlin was granted 66,897 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| May 25, 2021 Filed May 27, 2021 22:23 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 96,167 | $0.00 Strike: $8.03 | $0.00 |
DisclosureSEC source: 0001077183-21-000134 · wf-form4_162215415171071.xml · derivative · entry 6 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 96,167 shares Expires 2023-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On February 26, 2018, Mr. Shovlin was granted 288,500 stock options. These options vested ratably over the first three anniversary dates of the grant date. Read SEC document |
| May 25, 2021 Filed May 27, 2021 22:23 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 130,604 | $39.31 | $5,134,043.24 |
DisclosureSEC source: 0001077183-21-000134 · wf-form4_162215415171071.xml · nonDerivative · entry 4 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,101 Read SEC document |
| May 25, 2021 Filed May 27, 2021 22:23 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 14,067 | $28.33 | $398,518.11 |
DisclosureSEC source: 0001077183-21-000134 · wf-form4_162215415171071.xml · nonDerivative · entry 3 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 25, 2021 Filed May 27, 2021 22:23 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 16,724 | $19.60 | $327,790.40 |
DisclosureSEC source: 0001077183-21-000134 · wf-form4_162215415171071.xml · nonDerivative · entry 2 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 25, 2021 Filed May 27, 2021 22:23 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 96,167 | $8.03 | $772,221.01 |
DisclosureSEC source: 0001077183-21-000134 · wf-form4_162215415171071.xml · nonDerivative · entry 1 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:17 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 38,688 | $53.17 Strike: $53.17 | $2,057,040.96 |
DisclosureSEC source: 0001077183-21-000082 · wf-form4_161482063651429.xml · derivative · entry 7 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,688 Underlying: Common Stock · 38,688 shares Expires 2028-03-02 F6 · derivative.exercise_date: On March 2, 2021, Mr. Shovlin was granted 38,688 stock options. These options vest ratably over the first four anniversary dates of the grant date Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:17 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 6,827 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000082 · wf-form4_161482063651429.xml · nonDerivative · entry 3 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,747 Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:17 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 608 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000082 · wf-form4_161482063651429.xml · nonDerivative · entry 2 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,920 F2 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 2, 2021 vesting of restricted stock. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:17 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 742 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000082 · wf-form4_161482063651429.xml · nonDerivative · entry 1 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,528 F1 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 1, 2021 vesting of restricted stock. Read SEC document |
| July 30, 2020 Filed Aug 3, 2020 23:26 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,724 | $0.00 Strike: $19.60 | $0.00 |
DisclosureSEC source: 0001077183-20-000171 · wf-form4_159649719309566.xml · derivative · entry 5 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,173 Underlying: Common Stock · 16,724 shares Expires 2024-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On March 1, 2019, Mr. Shovlin was granted 66,897 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| July 30, 2020 Filed Aug 3, 2020 23:26 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 66,667 | $0.00 Strike: $7.52 | $0.00 |
DisclosureSEC source: 0001077183-20-000171 · wf-form4_159649719309566.xml · derivative · entry 4 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,667 shares Expires 2022-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On April 28, 2017, Mr. Shovlin was granted 200,000 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| July 30, 2020 Filed Aug 3, 2020 23:26 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 81,356 | $38.17 | $3,105,358.52 |
DisclosureSEC source: 0001077183-20-000171 · wf-form4_159649719309566.xml · nonDerivative · entry 3 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,270 Read SEC document |
| July 30, 2020 Filed Aug 3, 2020 23:26 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 16,724 | $19.60 | $327,790.40 |
DisclosureSEC source: 0001077183-20-000171 · wf-form4_159649719309566.xml · nonDerivative · entry 2 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,626 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2020 Filed Aug 3, 2020 23:26 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 66,667 | $7.52 | $501,335.84 |
DisclosureSEC source: 0001077183-20-000171 · wf-form4_159649719309566.xml · nonDerivative · entry 1 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,902 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 25, 2020 Filed May 27, 2020 21:20 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 5,405 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-20-000116 · wf-form4_159061438885210.xml · nonDerivative · entry 1 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,235 F1 · shares: Shares surrendered to NeoGenomics Inc. to satisfy the tax obligations in connection with the May 25, 2020 vesting of restricted stock. Read SEC document |
| March 04, 2020 Filed Mar 6, 2020 01:14 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 96,167 | $0.00 Strike: $8.03 | $0.00 |
DisclosureSEC source: 0001077183-20-000047 · wf-form4_158345723213644.xml · derivative · entry 3 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,167 Underlying: Common Stock · 96,167 shares Expires 2023-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On February 26, 2018, Mr. Shovlin was granted 288,500 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| March 04, 2020 Filed Mar 6, 2020 01:14 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 98,093 | $30.86 | $3,027,149.98 |
DisclosureSEC source: 0001077183-20-000047 · wf-form4_158345723213644.xml · nonDerivative · entry 2 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,640 Read SEC document |
| March 04, 2020 Filed Mar 6, 2020 01:14 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 96,167 | $8.03 | $772,221.01 |
DisclosureSEC source: 0001077183-20-000047 · wf-form4_158345723213644.xml · nonDerivative · entry 1 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,733 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 01:10 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock · Derivative | 56,271 | $28.33 Strike: $28.33 | $1,594,157.43 |
DisclosureSEC source: 0001077183-20-000035 · wf-form4_158328420295607.xml · derivative · entry 6 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,271 Underlying: Common Stock · 56,271 shares Expires 2027-03-02 F5 · derivative.exercise_date: On March 2, 2020, Mr. Shovlin was granted 56,271 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 01:10 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 8,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-20-000035 · wf-form4_158328420295607.xml · nonDerivative · entry 2 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,566 Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 01:10 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 810 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-20-000035 · wf-form4_158328420295607.xml · nonDerivative · entry 1 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,830 F1 · shares: Shares withheld by NeoGenomics Inc. to satisfy the tax obligations in connection with the March 1, 2020 vesting of restricted stock. Read SEC document |
| November 01, 2019 Filed Nov 4, 2019 23:07 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 35,801 | $22.74 | $814,114.74 |
DisclosureSEC source: 0001077183-19-000183 · wf-form4_157290881586746.xml · nonDerivative · entry 3 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,640 Read SEC document |
| October 31, 2019 Filed Nov 4, 2019 23:07 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 96,166 | $0.00 Strike: $8.03 | $0.00 |
DisclosureSEC source: 0001077183-19-000183 · wf-form4_157290881586746.xml · derivative · entry 4 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,334 Underlying: Common Stock · 96,166 shares Expires 2023-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On February 26, 2018, Mr. Shovlin was granted 288,500 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| October 31, 2019 Filed Nov 4, 2019 23:07 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 70,473 | $23.11 | $1,628,631.03 |
DisclosureSEC source: 0001077183-19-000183 · wf-form4_157290881586746.xml · nonDerivative · entry 2 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,441 Read SEC document |
| October 31, 2019 Filed Nov 4, 2019 23:07 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 96,166 | $8.03 | $772,212.98 |
DisclosureSEC source: 0001077183-19-000183 · wf-form4_157290881586746.xml · nonDerivative · entry 1 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 25, 2019 Filed May 30, 2019 00:51 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 6,559 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-19-000098 · wf-form4_155917744753839.xml · nonDerivative · entry 1 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,748 F1 · shares: Shares withheld by NeoGenomics Inc. to satisfy the tax obligations in connection with the May 25, 2019 vesting of restricted stock. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:31 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 66,667 | $0.00 Strike: $7.52 | $0.00 |
DisclosureSEC source: 0001077183-19-000058 · wf-form4_155717829283180.xml · derivative · entry 7 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,667 Underlying: Common Stock · 66,667 shares Expires 2022-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On April 28, 2017, Mr. Shovlin was granted 200,000 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:31 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 66,666 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001077183-19-000058 · wf-form4_155717829283180.xml · derivative · entry 5 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,666 shares Expires 2021-04-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On April 20, 2016, Mr. Shovlin was granted 200,000 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:31 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 66,667 | $22.14 | $1,476,007.38 |
DisclosureSEC source: 0001077183-19-000058 · wf-form4_155717829283180.xml · nonDerivative · entry 4 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,307 Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:31 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 52,680 | $22.14 | $1,166,335.20 |
DisclosureSEC source: 0001077183-19-000058 · wf-form4_155717829283180.xml · nonDerivative · entry 3 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,974 Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:31 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 66,667 | $7.52 | $501,335.84 |
DisclosureSEC source: 0001077183-19-000058 · wf-form4_155717829283180.xml · nonDerivative · entry 2 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:31 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 66,666 | $7.15 | $476,661.90 |
DisclosureSEC source: 0001077183-19-000058 · wf-form4_155717829283180.xml · nonDerivative · entry 1 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,987 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:07 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 66,897 | $19.60 Strike: $19.60 | $1,311,181.20 |
DisclosureSEC source: 0001077183-19-000035 · wf-form4_155182364657501.xml · derivative · entry 2 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,897 Underlying: Common Stock · 66,897 shares Expires 2024-03-01 F1 · derivative.exercise_date: On March 1, 2019, Mr. Shovlin was granted an option to purchase 66,897 shares of NeoGenomics, Inc. common stock. The options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:07 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 10,944 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-19-000035 · wf-form4_155182364657501.xml · nonDerivative · entry 1 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,321 Read SEC document |
| February 28, 2019 Filed Feb 28, 2019 22:05 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,986 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001077183-19-000015 · wf-form4_155139154286590.xml · derivative · entry 7 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,666 Underlying: Common Stock · 13,986 shares Expires 2021-04-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On April 20, 2016, Mr. Shovlin was granted 200,000 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| February 28, 2019 Filed Feb 28, 2019 22:05 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 13,986 | $7.15 | $99,999.90 |
DisclosureSEC source: 0001077183-19-000015 · wf-form4_155139154286590.xml · nonDerivative · entry 5 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2019 Filed Feb 28, 2019 22:05 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 44,135 | $19.23 | $848,716.05 |
DisclosureSEC source: 0001077183-19-000015 · wf-form4_155139154286590.xml · nonDerivative · entry 4 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,391 Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 22:05 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 66,666 | $0.00 Strike: $7.52 | $0.00 |
DisclosureSEC source: 0001077183-19-000015 · wf-form4_155139154286590.xml · derivative · entry 8 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,334 Underlying: Common Stock · 66,666 shares Expires 2022-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On April 28, 2017, Mr. Shovlin was granted 200,000 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 22:05 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 119,348 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001077183-19-000015 · wf-form4_155139154286590.xml · derivative · entry 6 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,652 Underlying: Common Stock · 119,348 shares Expires 2021-04-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On April 20, 2016, Mr. Shovlin was granted 200,000 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 22:05 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 141,879 | $18.88 | $2,678,675.52 |
DisclosureSEC source: 0001077183-19-000015 · wf-form4_155139154286590.xml · nonDerivative · entry 3 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,526 Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 22:05 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 66,666 | $7.52 | $501,328.32 |
DisclosureSEC source: 0001077183-19-000015 · wf-form4_155139154286590.xml · nonDerivative · entry 2 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,405 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 22:05 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 119,348 | $7.15 | $853,338.20 |
DisclosureSEC source: 0001077183-19-000015 · wf-form4_155139154286590.xml · nonDerivative · entry 1 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,739 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2018 Filed Nov 13, 2018 15:27 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 36,493 | $16.76 | $611,622.68 |
DisclosureSEC source: 0001077183-18-000109 · wf-form4_154212283634171.xml · nonDerivative · entry 3 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,391 Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 15:27 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $4.79 | $0.00 |
DisclosureSEC source: 0001077183-18-000109 · wf-form4_154212283634171.xml · derivative · entry 4 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires 2019-10-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On October 13, 2014, Mr. Shovlin was granted an option to purchase 300,000 shares. The options have time based vesting. On the first anniversary of the option grant date 75,000 shares vest. Then beginning on the thirteenth (13th) month through the fourth anniversary of the option grant date 6,250 shares will vest on a monthly basis. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 15:27 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 180,000 | $17.05 | $3,069,000.00 |
DisclosureSEC source: 0001077183-18-000109 · wf-form4_154212283634171.xml · nonDerivative · entry 2 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,884 Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 15:27 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 300,000 | $4.79 | $1,437,000.00 |
DisclosureSEC source: 0001077183-18-000109 · wf-form4_154212283634171.xml · nonDerivative · entry 1 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2018 Filed Jun 29, 2018 21:21 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 12,941 | $13.12 | $169,785.92 |
DisclosureSEC source: 0001077183-18-000062 · wf-form4_153030729405818.xml · nonDerivative · entry 1 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,884 F1 · price: Represents the average sales price. Read SEC document |
| May 25, 2018 Filed May 29, 2018 22:36 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock · Derivative | 16,666 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-18-000026 · wf-form4_152763335346523.xml · derivative · entry 3 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,334 Underlying: Common Stock · 16,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Each share of restricted stock represents the contingent right to receive one share of common stock upon vesting of the unit. F3 · derivative.exercise_date: Restricted stock will vest as follows; 16,666 vested on May 25, 2018 and 16,667 will vest on May 25, 2019 and 2020. F4 · derivative.expiration_date: These restricted stock will terminate upon the earliest of death, termination of employment or the last vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.